|
|
|
|
Study Supports Therapy for Children with CI
Office-based therapy with home reinforcement produced the most significant results of four methods testing for treating young patients with symptomatic convergence insufficiency, according to a first-of-its-kind clinical trial.The...
|
|
|
MedWatch - Innohep (tinzaparin sodium) Dear Healthcare Professional Letter Issued Re: Increased Risk of Death
ROCKVILLE, Md., Dec.31, 2008-Celgene has issued a Dear Healthcare Professional letter describing a controlled clinical study suggesting that Innohep may increase the risk for death, compared to unfractionated heparin when used to treat...
|
|
|
FDA Warns That Tinzaparin Increases Mortality Risk in Elderly Patients With Renal Insufficiency
_ FDA Warns That Tinzaparin Increases Mortality Risk in Elderly Patients With Renal Insufficiency.
|
|
|
Study: Office-based vergence therapy best for convergence insufficiency
The CITT found children improve more with this method than with a home program.Joseph Master ; Stephanie Vasta A large study found that combining 12 weeks of office-based therapy with home reinforcement is more effective for treating...
|
|
|
Glenohumeral Internal Rotation Deficits in Baseball Players With Ulnar Collateral Ligament Insufficiency
Background: The kinetic chain of the throwing motion functions to optimize efficiency of proximal segments to decrease force loads seen at smaller, distal segments such as the ulnar collateral ligament.Several studies have shown that...
|
|
|
Interim Innohep Study Results
The FDA has requested that Leo Pharma revise Innohep (tinzaparin sodium injection) labeling to better describe the overall study results which suggest that Innohep increases the risk of death for elderly patients 70 years of age and older...
|
|
|
Innohep (tinzaparin): Clinical study Stopped Early Because of Interim Finding of Increased All-cause Mortality
Innohep (tinzaparin sodium injection) This information reflects FDAs current analysis of available data concerning these drugs.Posting this information does not mean that FDA has concluded there is a cause and effect relationship between...
|
|
|
Tinzaparin Sodium Mortality Risk Not Limited to Patients Older Than 90 Years
The increased risk for mortality associated with tinzaparin sodium (Innohep, Pharmion Corp) may not be limited to patients aged 90 years and older, the US Food and Drug Administration (FDA) said yesterday in a news release.The warning was...
|
|
|
Innohep (tinzaparin): Clinical study Stopped Early Because of Interim Finding of Increased All-cause Mortality
Innohep (tinzaparin sodium injection) This information reflects FDAs current analysis of available data concerning these drugs.Posting this information does not mean that FDA has concluded there is a cause and effect relationship between...
|
|
|
FDA: Increased Risk of Mortality Associated With Tinzaparin Not Limited to Patients Over 90 Years
-- The US Food and Drug Administration (FDA) has received information about the Innohep in Renal Insufficiency Study (IRIS) that was stopped in February 2008 by the study's Data Safety Monitoring Committee because of an interim finding...
|
|
|
Digestive Care, Inc. Announces the Complete Submission of the NDA for Pancrecarb (pancrelipase)
/PRNewswire/ -- Digestive Care, Inc.(DCI) announced today that it has completed the submission of the New Drug Application ('NDA') for PANCRECARB(R) (pancrelipase), used in the treatment of Exocrine Pancreatic Insufficiency (...
|
|
|
Scientists find effective treatment for common childhood vision disorder
Scientists have found a more effective treatment for a common childhood eye muscle coordination problem called convergence insufficiency (CI).For words on a page to appear in focus a child's eyes must turn inward, or converge. In CI,...
|
